Asymchem, a global CDMO, has appointed Franck Mevellec as senior director, business development. Mevellec brings over 20 years of experience in the pharmaceutical industry, working across various aspects of drug development from R&D to sales.
 
Mevellec boasts a track record of success, having held key positions at industry leaders like Bayer Healthcare (R&D), Teva Pharmaceuticals (portfolio director), Minakem (BD director), and most recently, Seqens (global head of sales). He joins Asymchem with a focus on expanding the company’s footprint across Europe.
 
“Franck’s extensive experience and deep understanding of the European pharmaceutical market make him a valuable asset to our team,” said Jon Brice, SVP of business development at Asymchem. “His leadership and entrepreneurial spirit will be instrumental in driving our growth and strengthening our presence in this region.”
 
In his new role, Mevellec will leverage his expertise to develop new business opportunities for Asymchem, focusing on a wide range of services including flow chemistry, oligo and peptides, drug product development, and biologics.